Skip to main content

View full-text article in PMC

. 2022 Dec 8;45(1):29–43. doi: 10.1007/s11357-022-00705-1

Table 2.

Efficacy of the placebo and three NMN treated groups, comparisons of treatment over baseline within the same group

	Placebo, n = 20^d					300mg NMN, n = 20
	Baseline	Day 30	Day 60	p1^c	p2^c	Baseline	Day 30	Day 60	p1^c	p2^c
NAD(nM)^a,e	8.11 ± 5.16	9.83 ± 8.43	11.8 ± 9.4	0.44	0.14	11.8 ± 11.7	29.8 ± 20.1	32.6 ± 17.9	0.001	< 0.001
Six-minute walking(m)^a	325 ± 144	310 ± 125	330 ± 117	0.73	0.90	307 ± 108	350 ± 115	380 ± 144	0.23	0.079
Blood biological age(year)^a	39.8 ± 7.2	---	45.4 ± 8.2	---	0.029	42.2 ± 6.0	---	43.7 ± 6.7	---	0.46
HOMA-IR(ratio)^b	1.41 ± 0.79	---	2.09 ± 1.40	---	0.048	2.28 ± 1.43	---	2.28 ± 1.42	---	0.97
SF-36(score)^a	122 ± 14	127 ± 12	128 ± 13	0.2	0.12	124 ± 13	131 ± 12	137 ± 12	0.058	0.003
	600mg NMN, n = 20					900mg NMN, n = 20^d
	Baseline	Day 30	Day 60	p1^c	p2^c	Baseline	Day 30	Day 60	p1^c	p2^c
NAD(nM)^a,e	7.95 ± 3.29	39.0 ± 12.6	45.3 ± 11.8	< 0.001	< 0.001	10.5 ± 6.8	43.1 ± 14.3	48.5 ± 19.8	< 0.001	< 0.001
Six-minute walking(m)^a	290 ± 92	400 ± 86	435 ± 104	< 0.001	< 0.001	323 ± 113	425 ± 141	480 ± 128	0.016	< 0.001
Blood biological age(year)^a	45.2 ± 6.5	---	44.1 ± 6.4	---	0.57	44.3 ± 7.3	---	45.3 ± 5.9	---	0.64
HOMA-IR(ratio)^b	1.70 ± 1.05	---	2.14 ± 1.02	---	0.037	2.01 ± 1.26	---	2.67 ± 1.31	---	0.006
SF-36(score)^a	118 ± 16	129 ± 12	136 ± 12	0.015	< 0.001	122 ± 17	136 ± 12	140 ± 11	0.005	< 0.001

^aData are " mean ± SD" and normally distributed. Paired t test was used for comparison over baseline

^bData are " mean ± SD" and are not normally distributed. Wilcoxon signed-rank test was used for comparison over baseline

^cp1: comparison between day 30 and baseline, p2: comparison between day 60 and baseline. Statistical significance was set at p < 0.05

^dDue to 1 participant each from placebo and 900mg groups did not fast, HOMA-IR was based on 19 participants for these two groups

^eBlood NAD concentration data are the total concentration of “NAD⁺ + NADH” in serum